Overview

* ImmunoPrecise FY25 revenue was C$24.5 mln, missing analyst expectations

* Record Q4 revenue of C$7.0 mln, driven by BioStrand segment growth

* Q4 Adjusted EBITDA loss improved to C$0.3 mln, reflecting operational efficiency

Outlook

* Company anticipates completing divestiture of Dutch subsidiary soon

* ImmunoPrecise to focus on AI-based product development

* Company expects strategic steps to enhance core capabilities

* ImmunoPrecise aims to streamline operations with strategic priorities

Result Drivers

* BIOSTRAND GROWTH - BioStrand segment grew over 180% in FY25, contributing to improved gross margins

* OPERATIONAL EFFICIENCY - Q4 Adjusted EBITDA loss improved due to enhanced operational efficiency

* GROSS MARGIN IMPROVEMENT - Gross margin rose to 64% in Q4 FY25, driven by high-margin BioStrand revenues

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

FY Miss C$24.50 C$25.40

Revenue mln mln (2

Analysts

)

FY Net -C$30.20

Income mln

FY Gross C$13.50

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd ( IPA ) is $4.00, about 49.5% above its July 28 closing price of $2.02

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)